Patients received either BIIB122 or a placebo for 48 to 144 weeks.

Key Points Interested in Biogen Inc.? Here are five stocks we like better. Biogen's diranersen missed its primary endpoint in ...

Biogen and Denali’s Parkinson’s disease drug failed to significantly slow disease progression in a Phase 2b study, missing ...

High level results have led the companies to scrap the mid-stage trial, though Denali plans to continue independently running ...

Biogen and Denali Therapeutics halted development of experimental Parkinson's therapy BIIB122 after the Phase 2b LUMA study failed to meet its endpoints. Legal investigations have been launched into ...

(Reuters) -Biogen raised its annual profit forecast and beat estimates for quarterly results on Thursday, as strong demand for its rare disease drugs largely countered declining sales of its older ...

The Phase 2b LUMA study of BIIB122 in early-stage Parkinson’s disease did not meet its primary or secondary endpoints Based on data from the ...

Biogen and Denali have now confirmed that the results show BIIB122 (also known as DNL151) did not slow the progression of ...

Biogen said signals suggest the treatment decreases levels of tau and slows cognitive decline, particularly at the lowest ...

Biogen (BIIB) stock and Denali Therapeutics (DNLI) stock drop after the companies decide to halt development of a Parkinson’s ...

Somerset Therapeutics Private Ltd.'s proposed copy of Biogen Inc.'s Spinraza infringes three patents covering the spinal ...

Biogen’s Apellis acquisition consolidates a complement franchise spanning retinal and renal indications, with near-term label ...